Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide
1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate …

We report the discovery of a new monomeric peptide that reduces body weight and diabetic
complications in rodent models of obesity by acting as an agonist at three key metabolically …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4)
inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment of …

Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a 30‐residue peptide hormone released
from intestinal L cells following nutrient consumption. It potentiates the glucose‐induced …